MICHAEL D. DAKE, M.D.; JEFFREY A. GOLDEN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We read with great interest the recent article by Marchlinski and associates on the pulmonary toxicity of amiodarone (1). Previously published experience suggests that pulmonary injury may resolve when drug treatment is stopped and treatment with corticosteroids is started (2-6). But on the basis of immunofluorescence and electron microscopic studies, Marchlinski and colleagues have questioned the need for corticosteroid therapy because pathologic data suggested a metabolic rather than an immunologic process. In addition, the clinical benefit of steroid therapy beyond that achieved by simply discontinuing the amiodarone remains unclear because all reported patients who had reversal of
DAKE MD, GOLDEN JA. Amiodarone and Pulmonary Effects. Ann Intern Med. ;98:1028. doi: 10.7326/0003-4819-98-6-1028_2
Download citation file:
Published: Ann Intern Med. 1983;98(6):1028.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use